Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.

ABSTRACT:

Background

We examined the efficacy of olanzapine for the prevention of nausea and vomiting in patients receiving highly emetogenic chemotherapy.

Methods

In a randomized, double-blind, phase 3 trial, we compared olanzapine with placebo, in combination with dexamethasone, aprepitant or fosaprepitant, and a 5-hydroxytryptamine type 3-receptor antagonist, in patients with no previous chemotherapy who were receiving cisplatin (≥70 mg per square meter of body-surface area) or cyclophosphamide-doxorubicin. The doses of the three concomitant drugs administered before and after chemotherapy were similar in the two groups. The two groups received either 10 mg of olanzapine orally or matching placebo daily on days 1 through 4. Nausea prevention was the primary end point; a complete re

SUBMITTER: Navari RM 

PROVIDER: S-EPMC5344450 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature